Tocagen Inc. (TOCA) PT Lowered to $10 at Chardan Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Tocagen Inc. (TOCA) PT Lowered to $16 at Ladenburg Thalmann
May 22, 2019 6:37 AM EDTLadenburg Thalmann analyst Wangzhi Li lowered the price target on Tocagen Inc. (NASDAQ: TOCA) to $16.00 (from $20.00) while maintaining a Buy rating.
... MoreTocagen Inc. (TOCA) PT Lowered to $5 at SVB Leerink
May 22, 2019 6:14 AM EDTSVB Leerink analyst Daina Graybosch lowered the price target on Tocagen Inc. (NASDAQ: TOCA) to $5.00 (from $11.00) while maintaining a Market Perform rating.
... MoreTocagen (TOCA) Says Toca 5 Pivotal Phase 3 Clinical Trial in Patients with Recurrent Brain Cancer Continues Without Modification at Planned Interim Analysis
May 21, 2019 4:10 PM EDTTocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the Toca 5 Phase 3 clinical trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma (HGG) continues without modification following a planned interim analysis of data conducted by an Independent Data Monitoring Committee (IDMC). The... More
